Navigation Links
Sinobiopharma, Inc. Signs Sales Contract for Flagship Project
Date:4/13/2009

NANTONG CITY, China, April 13 /PRNewswire-FirstCall/ -- Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) is pleased to announce that it has signed the sales contracts totaling 1.5 million units for its flagship product, a patented formulation of Cisatracurium Besylate that is China's top-selling pre-surgical skeletal muscle relaxant.

"This contract is the beginning of an exciting time for the company," said Sinobiopharma CEO, Dr. Huang. "Not only does this take the company's revenue from $1 million to $15 million, but there are many products still coming down the pipeline." The commitment for the 1.5 million units is over a 1 year period and is expected to generate in excess of $15 million USD in revenue during this fiscal year.

The contracts are with Sinobiopharma's business agents, who distribute the Company's products in 30 provinces and key major cities throughout China.

The Company's Chinese patented formulation of Cisatracurim Besylate, is the world's first that can be stored at room temperature. Competitors' versions must be kept at 2 to 8 degrees C. Compared to other neuromuscular blocking agents, Sinobiopharma's intravenously administered formulation is immediate in onset and longer in duration. Within 14 months of its launch in China in late 2006, it is now in use in more than 700 hospitals across China.

As part of its drive to expand its marketing and distribution capacity with new channels, Sinobiopharma is negotiating to acquire 100-percent ownership of a drug distribution company, Nanjing Langkun Medicine Co. Ltd., to accelerate growth in sales revenue in 2009.

Sinobiopharma's expansion strategy also includes targeted acquisitions that will expand its first-to-market drug pipeline and advancing new development of innovative drugs that will consolidate leadership position in its chosen therapeutic areas.

About Sinobiopharma

Sinobiopharma Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

FORWARD LOOKING STATEMENTS

This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law.


'/>"/>
SOURCE Sinobiopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. HomeSwimmer, Ltd. Signs Olympic Medalist Josh Davis
2. Soarian Device Connect v2.0 Helps Streamline Vital Signs Collection Workflow at Greenwood Leflore Hospital
3. ULURU Inc. Signs Offer Letter to Acquire York Pharma plc
4. enlyten Signs Shaquille ONeal as Official Spokesperson
5. Nashville's eDoc4u Signs Partnership Agreement With Saint Thomas Health Services
6. Occupational Therapy Practitioners Identify Early Signs Of Autism Spectrum Disorder, Help Families Participate In Daily Routines
7. Al Copeland Foundation Signs on as Title Sponsor of 2009 Chris Paul Basketball Camp
8. New Dakim Campaign Promotes Brain Fitness for Seniors with Elderly Holding Signs Declaring My Brain Is Not Retired
9. Samplify Expands Global Distribution Channel; Signs Top-Ranked Chinese Distributor, Excelpoint
10. Stereotaxis Signs Agreement With Leading Leasing Specialist to Offer Alternative Financing to Hospital Customers
11. MedCom Signs National Provider Contract With AmeriPlan Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... CA (PRWEB) , ... February 23, 2017 , ... Hamlin ... to announce that they are sponsoring a raffle. Throughout the month of February, patients ... will receive a gift card for a dinner for two at the Cheesecake Factory. ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... for the National Institute for Health and Care Excellence (NICE) framework. ... the National Health Service (NHS) to search, order and purchase medical and healthcare-related ...
(Date:2/23/2017)... ... 23, 2017 , ... Dr. David Mahon leads Siena Dental, a comprehensive dental ... named a 2017 Top Patient Rated Henderson Dentist by Find Local Doctors ... local physicians and dentists who have earned high ratings and superior patient reviews from ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
(Date:2/23/2017)... ... February 23, 2017 , ... Healthcare Research & Analytics® (HRA®) ... fight against cancer, has produced a seminal study that asked cancer survivors and ... findings in a webinar, Defining Compassionate Care Through the Voices of Patients and ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... CITY, Calif., Feb. 23, 2017 Nevro Corp. (NYSE: ... evidence-based solutions for the treatment of chronic pain, today reported ... December 31, 2016. 2016 Accomplishment & Highlights: ... full year 2016, an increase of 228% as reported, over ... for 2016, an increase of 612% over the prior year ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... to their offering. ... The latest research Fibromyalgia Drugs Price Analysis and Strategies - ... market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Fibromyalgia ...
(Date:2/23/2017)... , February 23, 2017 ... Market by Product (X-ray Imaging Digital, Analog), MRI (Closed, ... (OB/GYN, MSK, Cardiology, Oncology), End User (Hospitals, Imaging Centers) ... report studies the global market over the forecast period ... reach ~USD 36.43 Billion by 2021, at a CAGR ...
Breaking Medicine Technology: